Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma
- 1 July 2000
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 28 (7) , 858-870
- https://doi.org/10.1016/s0301-472x(00)00169-7
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systemsBone Marrow Transplantation, 1997
- CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cellsBritish Journal of Haematology, 1996
- Development of a Clinically Applicable High-Speed Flow Cytometer for the Isolation of Transplantable Human Hematopoietic Stem CellsJournal of Hematotherapy, 1995
- Contamination of peripheral blood by monoclonal B cells following treatment of multiple myeloma by high‐dose chemotherapyBritish Journal of Haematology, 1993
- Immunomagnetic Separation of CD34+Cells from Human Bone Marrow, Cord Blood, and Mobilized Peripheral BloodJournal of Hematotherapy, 1993
- VAD‐based regimens as primary treatment for multiple myelomaAmerican Journal of Hematology, 1990
- INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMAThe Lancet, 1989
- ALTERED IMMUNOLOGIC RECONSTITUTION AFTER STANDARD-DOSE CHEMOTHERAPY OR HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW SUPPORTTransplantation, 1988
- NATURAL KILLER FUNCTION FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATIONTransplantation, 1988
- Lymphocyte function after autologous bone marrow transplantation (BMT): a comparison with patients treated with allogeneic BMT and with chemotherapy onlyBritish Journal of Haematology, 1986